close read more

Toward a new model to accelerate innovation

Dr CLAUDE BERTRAND

Executive Vice President Research & Development


Our R&D model is constantly evolving to accelerate the delivery of medicines that respond to the real needs of patients. The establishment of the future Servier Paris-Saclay Research Institute is a perfect illustration of our desire to pursue more open, agile, and productive research to serve patients. This new R&D model is based on three pillars.

 

Focusing on projects with high added-value for patients

As a medium-sized pharmaceutical group, we need to focus on high-value projects designed with and for patients. We have made strong and structural choices in our pipeline of projects in order to focus our energies on the most promising ones.

 

Building on science and translational medicine

Translational research aims to improve our understanding of the disease and accelerate the transition from discovery to clinical development of drug candidates, while at the same time developing markers that will allow us to assess their efficacy and safety more quickly. It facilitates the development of personalized therapeutic solutions that are better adapted to the needs of each patient. This approach enables us to select the best medicines and increases our chances of success.

 

Capitalizing on the benefits of digital technology

The integration of digital technology at all levels of our R&D value chain is a powerful lever for greater agility, efficiency, and productivity. By combining the most advanced data processing technologies with our expertise, we will be able to speed up the iteration cycles of molecule identification in the future. We continually test new tools and will soon launch a major digital initiative to speed up clinical trials and to connect with patients as closely as possible throughout their illness.

 

“We need to change the way we work, build more agile R&D and constantly instill a sense of urgency in our researchers. This is crucial for accelerating the availability of medicines for patients.”